TY - JOUR
T1 - Dual Toll-Like Receptor Targeting Liposomal Spherical Nucleic Acids
AU - Ferrer, Jennifer R.
AU - Wertheim, Jason A.
AU - Mirkin, Chad A.
N1 - Funding Information:
Research reported in this publication was supported by the National Cancer Institute under Award U54CA199091 awarded to C.A.M., the National Institute of General Medical Sciences under Award F31GM119392 and Award T32GM105538 awarded to J.R.F., and the National Institute of Diabetes and Digestive and Kidney Diseases under Award K08DK101757 awarded to J.A.W. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. J.A.W. acknowledges funding support by the International Institute for Nanotechnology at Northwestern University and the NTU-Northwestern Institute for Nanomedicine (NNIN), as well as a grant from the Julius Frankel Foundation. This research was also supported by the Air Force Research Laboratory under Award FA8650-15-2-5518 awarded to C.A.M. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the Air Force Research Laboratory or the U.S. Government. Research was performed using resources from the International Institute of Nanotechnology, the Simpson Querry Institute Analytical BioNa-noTechnology Equipment Core, the Northwestern University Quantitative Bioelement Imaging Center, the Robert H. Lurie Comprehensive Cancer Center Flow Cytometry Core, the Northwestern Center for Comparative Medicine, and the Feinberg School of Medicine Immune Monitoring Core.
PY - 2019/3/20
Y1 - 2019/3/20
N2 - Liposomal spherical nucleic acids (LSNAs) are a class of nanomaterial used broadly for biomedical applications. Their intrinsic capacity to rapidly enter cells and engage cell surface and intracellular ligands stems from their unique three-dimensional architecture, which consists of densely packed and uniformly oriented oligonucleotides on the surface of a liposomal core. Such structures are promising for therapeutics because they can carry chemical cargo within the lipid core in addition to the nucleic acids that define them, in principle enabling delivery of multiple signals to a single cell. On the basis of these traits, we have designed novel dual-targeting LSNAs that deliver a nucleic acid specific for TLR9 inhibition and a small molecule (TAK-242) that inhibits TLR4. Toll-like receptors (TLRs) play a large role in pathogen recognition and disease initiation, and TLR subtypes are differentially located within the lipid membranes of the cell surface and within intracellular endosomes. Oftentimes, in acute or chronic inflammatory conditions, multiple TLRs are activated, leading to stimulation of distinct, and sometimes overlapping, downstream pathways. As such, these inflammatory conditions may respond to attenuation of more than one initiating receptor. We show that dual targeting LSNAs, comprised of unilamellar liposomal cores, the INH-18 oligonucleotide sequence, and TAK-242 robustly inhibit TLR-9 and TLR-4 respectively, in engineered TLR reporter cells and primary mouse peritoneal macrophages. Importantly, the LSNAs exhibit up to a 10- and a 1000-fold increase, respectively, in TLR inhibition compared to the linear sequence and TAK-242 alone. Moreover, the timing of delivery is shown to be a critical factor in effecting TLR-inhibition, with near-complete TLR-4 inhibition occurring when cells were pretreated with SNAs for 4 h prior to stimulation. The most pronounced effect observed from this approach is the benefit of delivering the small molecule within the SNA via the receptor-mediated internalization pathway common to SNAs.
AB - Liposomal spherical nucleic acids (LSNAs) are a class of nanomaterial used broadly for biomedical applications. Their intrinsic capacity to rapidly enter cells and engage cell surface and intracellular ligands stems from their unique three-dimensional architecture, which consists of densely packed and uniformly oriented oligonucleotides on the surface of a liposomal core. Such structures are promising for therapeutics because they can carry chemical cargo within the lipid core in addition to the nucleic acids that define them, in principle enabling delivery of multiple signals to a single cell. On the basis of these traits, we have designed novel dual-targeting LSNAs that deliver a nucleic acid specific for TLR9 inhibition and a small molecule (TAK-242) that inhibits TLR4. Toll-like receptors (TLRs) play a large role in pathogen recognition and disease initiation, and TLR subtypes are differentially located within the lipid membranes of the cell surface and within intracellular endosomes. Oftentimes, in acute or chronic inflammatory conditions, multiple TLRs are activated, leading to stimulation of distinct, and sometimes overlapping, downstream pathways. As such, these inflammatory conditions may respond to attenuation of more than one initiating receptor. We show that dual targeting LSNAs, comprised of unilamellar liposomal cores, the INH-18 oligonucleotide sequence, and TAK-242 robustly inhibit TLR-9 and TLR-4 respectively, in engineered TLR reporter cells and primary mouse peritoneal macrophages. Importantly, the LSNAs exhibit up to a 10- and a 1000-fold increase, respectively, in TLR inhibition compared to the linear sequence and TAK-242 alone. Moreover, the timing of delivery is shown to be a critical factor in effecting TLR-inhibition, with near-complete TLR-4 inhibition occurring when cells were pretreated with SNAs for 4 h prior to stimulation. The most pronounced effect observed from this approach is the benefit of delivering the small molecule within the SNA via the receptor-mediated internalization pathway common to SNAs.
UR - http://www.scopus.com/inward/record.url?scp=85062889522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062889522&partnerID=8YFLogxK
U2 - 10.1021/acs.bioconjchem.9b00047
DO - 10.1021/acs.bioconjchem.9b00047
M3 - Article
C2 - 30830754
AN - SCOPUS:85062889522
VL - 30
SP - 944
EP - 951
JO - Bioconjugate Chemistry
JF - Bioconjugate Chemistry
SN - 1043-1802
IS - 3
ER -